TS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tenaris SA (TS) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the stock has shown positive momentum in the pre-market and has received several upward revisions in price targets from analysts, the lack of strong proprietary trading signals, mixed financial performance, and the absence of recent congress trading data make it prudent to hold off on immediate investment. The investor may consider monitoring the stock for better entry points or clearer signals.
The technical indicators show a bullish trend with the MACD histogram above 0 and positively contracting, and the moving averages (SMA_5 > SMA_20 > SMA_200) signaling upward momentum. However, the RSI at 79.603 is in the neutral zone, suggesting no clear overbought or oversold conditions. Key resistance levels are at R1: 54.096 and R2: 56.05, with support at S1: 47.77 and S2: 45.816.
Hedge funds are significantly increasing their positions in the stock, with a 357.08% increase in buying over the last quarter.
Analysts have raised their price targets, with several maintaining Buy or Overweight ratings.
The company has completed a substantial share buyback program, which could support the stock price in the short term.
The company's net income and EPS have declined YoY, indicating weaker profitability despite revenue growth.
The termination of the share buyback program due to market volatility may signal caution from management.
The broader market sentiment is negative, with the S&P 500 down 0.75% in pre-market trading.
In Q4 2025, Tenaris reported a 5.27% YoY increase in revenue to $2.995 billion. However, net income dropped by 13.05% YoY to $448.87 million, and EPS decreased by 6.38% YoY to $0.44. Gross margin improved by 4.47% YoY to 33.89%, indicating some operational efficiency gains.
Recent analyst ratings are mixed but skew positive. Stifel, Barclays, and TD Cowen have raised their price targets and maintained Buy or Overweight ratings, with targets ranging from $56 to $59. Goldman Sachs and Morgan Stanley remain more cautious with Neutral and Underweight ratings, citing limited near-term catalysts and concerns over U.S. shale exposure.
